• Long Term Treatment of Mild Cognitive Impairment (MCI) with Transdermal Nicotine: The MIND Study (Newhouse)
    • Multi-center clinical trial to test whether daily transdermal nicotine will produce sustained cognitive, clinical, and modify imaging and biochemical markers in patients with Mild Cognitive Impairment (MCI). 
  • Phase 1 First-In-Human Study of the Muscarinic M1 Positive Allosteric Modulator VU319 (Newhouse)
    • Initial human safety and target engagement testing of a novel cholinergic drug developed at Vanderbilt for Alzheimer’s disease.
  • Connectivity Affecting the Antidepressant Response: The CAARE study (Taylor)
    • To understand the relationship between brain connectivity and how older adults respond to antidepressant medications and depression relapse.
  • Depressed Mood Improvement through Nicotine Dosing: D-MIND Study (Taylor)
  • The effects of transdermal nicotine on depression and memory performance in older adults with depression.
  • History of Major Depressive Disorder and Estradiol Effects on Psychosocial Stress Response and Emotional Episodic Memory (Albert).
  • Nicotinic Treatment of Post-Cancer Chemotherapy Subjective Cognitive Impairment (Vega, Newhouse).
  • Cholinergic Correlates of Age and Impaired Cognitive Ability in HIV-Positive Individuals (Kamkwalala, Newhouse).
  • Efficacy And Safety Study Of Crenezumab In Patients With Prodromal To Mild Alzheimer’s Disease (Newhouse).